Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

639
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
639
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

188
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
188
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

759
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
759
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

415
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
415

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the slope: prognostic utility of the VE/VCO<sub>2</sub> intercept in chronic heart failure.

Open heart·2026
Same author

How low-temperature welding affects the nanostructure of nanowire junctions.

Nanoscale·2026
Same author

Assessment of double anaerobic threshold in trained subjects.

Respiratory physiology & neurobiology·2026
Same author

A modified Canadian Syncope Risk Score for emergency department use.

Internal and emergency medicine·2026
Same author

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk score.

Vascular pharmacology·2025
Same author

Pathophysiology of Pulmonary Arterial Hypertension: Focus on Vascular Endothelium as a Potential Therapeutic Target.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jan 4, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K

Liver disease and heart failure.

Michele Correale1, Lucia Tricarico2, Alessandra Leopizzi2

  • 1Unit of Cardiology, Ospedali Riuniti University Hospital of Foggia, Foggia, Italy - opsfco@tin.it.

Panminerva Medica
|November 1, 2019
PubMed
Summary

Liver and heart conditions often coexist due to systemic diseases. Early assessment of liver function tests (LFTs) in acute decompensated heart failure (ADHF) is crucial for effective patient management and improved outcomes.

More Related Videos

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
04:49

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension

Published on: June 14, 2024

1.1K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.6K

Related Experiment Videos

Last Updated: Jan 4, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K
Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
04:49

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension

Published on: June 14, 2024

1.1K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.6K

Area of Science:

  • Cardiology
  • Hepatology
  • Internal Medicine

Background:

  • Systemic conditions like inflammatory diseases, infections, alcoholism, and non-alcoholic fatty liver disease (NAFLD) can impact both cardiac and hepatic function.
  • Acute decompensated heart failure (ADHF) can lead to acute ischemic hepatitis, while chronic heart failure (HF) may result in congestive hepatopathy (CH).

Purpose of the Study:

  • To emphasize the importance of evaluating both cardiac and hepatic function in patients with advanced HF.
  • To highlight the predictive value of hepatic function tests (LFTs) for patient outcomes.

Main Methods:

  • Review of clinical presentations and laboratory findings in patients with coexisting heart and liver conditions.
  • Analysis of how abnormal LFTs indicate specific mechanisms of liver injury (congestion or ischemia).

Main Results:

  • Abnormal LFTs can signify liver congestion or ischemia, guiding treatment decisions in acute heart failure (AHF).
  • Right-sided HF is present in over 90% of patients with clinically apparent ischemic hepatitis.
  • Systemic disorders affecting metal accumulation or metabolism can lead to hypertrophic cardiomyopathy (HCM) and liver issues.

Conclusions:

  • Liver function tests (LFTs) are recommended in the early management of ADHF.
  • Physicians, particularly cardiologists and internists, need training in evaluating LFTs and recognizing systemic diseases affecting both heart and liver.
  • Early identification of signs and symptoms of rare diseases and liver conditions that may mimic HF is critical for accurate diagnosis and treatment.